Zusammenfassung
Während der letzten 10 Jahre etablierten sich neue Erkenntnisse zur immunvermittelten Genese von Erkrankungen der grauen Substanz des Zentralnervensystems. Diese gehen in ca. 80% der Fälle mit Anfällen einher und imponieren häufig als pharmakoresistente Epilepsien. Wesentlich für die Charakterisierung dieser Erkrankungen war die Entdeckung von Auto-Antikörpern (AK) gegen neuronale Oberflächenantigene (NOA). Immunvermittelte Epilepsien zeigen oft ein unzureichendes Ansprechen auf Antiepileptika. Sie sprechen jedoch in vielen Fällen auf Immuntherapien an. Insofern bieten sich hier Chancen für eine Überwindung von Antiepileptikaresistenz durch immunologische Therapien.
Summary
During the last decade new knowledge on immune-mediated disorders of the grey substance of the central nervous system (CNS) has been generated. These conditions are associated with seizures in approximately 80% of cases and often present as drug-resistant epilepsies. The discovery of autoantibodies against neural surface antigens was essential for the identification of these disorders. Immune-mediated epilepsies often respond poorly to antiepileptic drugs; however, they do respond in many cases to immunological therapy which offers a chance of overcoming resistance to antiepileptic drugs by immunological treatment.
Literatur
Ances BM, Vitaliani R, Taylor RA et al (2005) Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128:1764–1777
Bien CG, Elger CE (2007) Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 10:529–538
Bien CG, Rüegg S, Schmutzhard E et al (2012) Immunvermittelte Erkrankungen der grauen ZNS-Substanz sowie Neurosarkoidose. In: Diener HC, Putzki N (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme, Stuttgart/New York, S 476–487
Bien CG, Urbach H, Schramm J et al (2007) Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 69:1236–1244
Bien CG, Vincent A, Barnett MH et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638
Boronat A, Gelfand JM, Gresa-Arribas N et al (2012) Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. Ann Neurol (in press)
Castillo P, Woodruff B, Caselli R et al (2006) Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 63:197–202
Dalmau J, Lancaster E, Martinez-Hernandez E et al (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63–74
Dalmau J, Tuzun E, Wu HY et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36
Geschwind MD, Tan KM, Lennon VA et al (2008) Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol 65:1341–1346
Graus F, Boronat A, Xifro X et al (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859
Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psych 75:1135–1140
Gultekin SH, Rosenfeld MR, Voltz R et al (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494
Holzer FJ, Rossetti AO, Heritier-Barras AC et al (2012) Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol 68:310–317
Irani SR, Alexander S, Waters P et al (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133:2734–2748
Irani SR, Bera K, Waters P et al (2010) N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667
Irani SR, Bien CG, Lang B (2011) Autoimmune epilepsies. Curr Opin Neurol 24:146–153
Irani SR, Michell AW, Lang B et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900
Lai M, Hughes EG, Peng X et al (2009) AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65:424–434
Lancaster E, Lai M, Peng X et al (2010) Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9:67–76
Lancaster E, Martinez-Hernandez E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77:179–189
Lancaster E, Martinez-Hernandez E, Titulaer MJ et al (2011) Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 77:1698–1701
Liimatainen S, Peltola M, Sabater L et al (2010) Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 51:760–767
Malter MP, Helmstaedter C, Urbach H et al (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478
Mcknight K, Jiang Y, Hart Y et al (2005) Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65:1730–1736
Niehusmann P, Dalmau J, Rudlowski C et al (2009) Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 66:458–464
Novillo-Lopez ME, Rossi JE, Dalmau J et al (2008) Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. Neurology 70:728–729
Schmitt SE, Pargeon K, Frechette ES et al (2012) Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100
Shavit YB, Graus F, Probst A et al (1999) Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 45:255–258
Stich O, Klages E, Bischler P et al (2012) SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand 125:326–331
Vincent A, Bien CG, Irani SR et al (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759–772
Voltz R, Blaes F, Rauer S et al (2008) Paraneoplastische Syndrome. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme, Stuttgart, S 654 ff
Wieser S, Kelemen A, Barsi P et al (2005) Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord 7:205–211
Zuliani L, Graus F, Giometto B et al (2012) Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psych 83:638–645
Interessenkonflikt
Der korrespondierende Autor weist für sich und seinen Koautor auf folgende Beziehungen hin: C.G. Bien und C. Kramme führen im Labor ihrer Klinik Serum- und Liquordiagnostik bezüglich der im Text beschriebenen Antikörper durch. Für diese Diagnostik rechnet ihre Klinik mit auswärtigen Einsendern Gebühren ab. C.G. Bien erhielt Reisekostenunterstützung von folgenden Firmen: Eisai, UCB, Desitin, Grifols; Vortragshonorare von folgenden Firmen: Eisai, UCB, GlaxoSmithKline, Desitin; Honorare für die Mitarbeit in Advisory Boards der folgenden Firmen: UCB, Eisai.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kramme, C., Bien, C. Immunvermittelte Epilepsien und Enzephalopathien. Nervenarzt 84, 442–449 (2013). https://doi.org/10.1007/s00115-012-3605-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-012-3605-7
Schlüsselwörter
- Immunvermittelte Epilepsie
- Neuronale Oberflächenantigene
- Onkoneurale Antikörper
- Limbische Enzephalitis
- Faziobrachiale dystone Anfälle